Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Global Outlook and Forecast 2022-2028
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune motor sensory peripheral neuropathy with chronic demyelination of the proximal peripheral nerves as the main lesion. It belongs to chronic acquired demyelinating multiple neuropathy (ADP), the most common type of CADP, and presents a course of chronic progression or remission - recurrence.
This report contains market size and forecasts of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Global, including the following market information:
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Corticosteroid Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) include Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols and CSL Behring (CSL Limited), etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segment Percentages, by Type, 2021 (%)
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segment Percentages, by Application, 2021 (%)
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
This report contains market size and forecasts of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Global, including the following market information:
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Corticosteroid Therapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) include Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols and CSL Behring (CSL Limited), etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segment Percentages, by Type, 2021 (%)
- Corticosteroid Therapy
- IVIG Treatment
- Plasma Exchange Therapy
- Immunosuppressive Drug Therapy
- Immunomodulator Therapy
- Other
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segment Percentages, by Application, 2021 (%)
- Hospital
- Specialist Neurology Clinic
- Research and Academic Laboratories
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Teijin Pharma
- Shire
- Pfizer
- Octapharma
- Momenta Pharmaceuticals
- Mitsubishi Tanabe Pharma Corporation
- Kedrion
- Grifols
- CSL Behring (CSL Limited)
- Bio Products Laboratory
- Baxter
- MedDay Pharmaceuticals
- GeNeuro Pharmaceuticals
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) OVERALL MARKET SIZE
2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size: 2021 VS 2028
2.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players in Global Market
3.2 Top Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies Ranked by Revenue
3.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Companies
3.4 Top 3 and Top 5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies in Global Market, by Revenue in 2021
3.5 Global Companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players in Global Market
3.6.1 List of Global Tier 1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies
3.6.2 List of Global Tier 2 and Tier 3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Markets, 2021 & 2028
4.1.2 Corticosteroid Therapy
4.1.3 IVIG Treatment
4.1.4 Plasma Exchange Therapy
4.1.5 Immunosuppressive Drug Therapy
4.1.6 Immunomodulator Therapy
4.1.7 Other
4.2 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue & Forecasts
4.2.1 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2022
4.2.2 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2023-2028
4.2.3 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Specialist Neurology Clinic
5.1.4 Research and Academic Laboratories
5.2 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue & Forecasts
5.2.1 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2022
5.2.2 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2023-2028
5.2.3 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2021 & 2028
6.2 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue & Forecasts
6.2.1 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2022
6.2.2 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2023-2028
6.2.3 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028
6.3.2 US Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.3.3 Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.3.4 Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028
6.4.2 Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.4 U.K. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.5 Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.6 Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.7 Nordic Countries Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.8 Benelux Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028
6.5.2 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.5.3 Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.5.4 South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.5.5 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.5.6 India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028
6.6.2 Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.6.3 Argentina Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028
6.7.2 Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.7.3 Israel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.7.4 Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.7.5 UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Teijin Pharma
7.1.1 Teijin Pharma Corporate Summary
7.1.2 Teijin Pharma Business Overview
7.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.1.4 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.1.5 Teijin Pharma Key News
7.2 Shire
7.2.1 Shire Corporate Summary
7.2.2 Shire Business Overview
7.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.2.4 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.2.5 Shire Key News
7.3 Pfizer
7.3.1 Pfizer Corporate Summary
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.3.4 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.3.5 Pfizer Key News
7.4 Octapharma
7.4.1 Octapharma Corporate Summary
7.4.2 Octapharma Business Overview
7.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.4.4 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.4.5 Octapharma Key News
7.5 Momenta Pharmaceuticals
7.5.1 Momenta Pharmaceuticals Corporate Summary
7.5.2 Momenta Pharmaceuticals Business Overview
7.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.5.4 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.5.5 Momenta Pharmaceuticals Key News
7.6 Mitsubishi Tanabe Pharma Corporation
7.6.1 Mitsubishi Tanabe Pharma Corporation Corporate Summary
7.6.2 Mitsubishi Tanabe Pharma Corporation Business Overview
7.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.6.4 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.6.5 Mitsubishi Tanabe Pharma Corporation Key News
7.7 Kedrion
7.7.1 Kedrion Corporate Summary
7.7.2 Kedrion Business Overview
7.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.7.4 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.7.5 Kedrion Key News
7.8 Grifols
7.8.1 Grifols Corporate Summary
7.8.2 Grifols Business Overview
7.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.8.4 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.8.5 Grifols Key News
7.9 CSL Behring (CSL Limited)
7.9.1 CSL Behring (CSL Limited) Corporate Summary
7.9.2 CSL Behring (CSL Limited) Business Overview
7.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.9.4 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.9.5 CSL Behring (CSL Limited) Key News
7.10 Bio Products Laboratory
7.10.1 Bio Products Laboratory Corporate Summary
7.10.2 Bio Products Laboratory Business Overview
7.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.10.4 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.10.5 Bio Products Laboratory Key News
7.11 Baxter
7.11.1 Baxter Corporate Summary
7.11.2 Baxter Business Overview
7.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.11.4 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.11.5 Baxter Key News
7.12 MedDay Pharmaceuticals
7.12.1 MedDay Pharmaceuticals Corporate Summary
7.12.2 MedDay Pharmaceuticals Business Overview
7.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.12.4 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.12.5 MedDay Pharmaceuticals Key News
7.13 GeNeuro Pharmaceuticals
7.13.1 GeNeuro Pharmaceuticals Corporate Summary
7.13.2 GeNeuro Pharmaceuticals Business Overview
7.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.13.4 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.13.5 GeNeuro Pharmaceuticals Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) OVERALL MARKET SIZE
2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size: 2021 VS 2028
2.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players in Global Market
3.2 Top Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies Ranked by Revenue
3.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Companies
3.4 Top 3 and Top 5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies in Global Market, by Revenue in 2021
3.5 Global Companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players in Global Market
3.6.1 List of Global Tier 1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies
3.6.2 List of Global Tier 2 and Tier 3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Markets, 2021 & 2028
4.1.2 Corticosteroid Therapy
4.1.3 IVIG Treatment
4.1.4 Plasma Exchange Therapy
4.1.5 Immunosuppressive Drug Therapy
4.1.6 Immunomodulator Therapy
4.1.7 Other
4.2 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue & Forecasts
4.2.1 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2022
4.2.2 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2023-2028
4.2.3 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Specialist Neurology Clinic
5.1.4 Research and Academic Laboratories
5.2 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue & Forecasts
5.2.1 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2022
5.2.2 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2023-2028
5.2.3 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2021 & 2028
6.2 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue & Forecasts
6.2.1 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2022
6.2.2 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2023-2028
6.2.3 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028
6.3.2 US Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.3.3 Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.3.4 Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028
6.4.2 Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.4 U.K. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.5 Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.6 Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.7 Nordic Countries Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.4.8 Benelux Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028
6.5.2 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.5.3 Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.5.4 South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.5.5 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.5.6 India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028
6.6.2 Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.6.3 Argentina Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028
6.7.2 Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.7.3 Israel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.7.4 Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
6.7.5 UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Teijin Pharma
7.1.1 Teijin Pharma Corporate Summary
7.1.2 Teijin Pharma Business Overview
7.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.1.4 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.1.5 Teijin Pharma Key News
7.2 Shire
7.2.1 Shire Corporate Summary
7.2.2 Shire Business Overview
7.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.2.4 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.2.5 Shire Key News
7.3 Pfizer
7.3.1 Pfizer Corporate Summary
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.3.4 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.3.5 Pfizer Key News
7.4 Octapharma
7.4.1 Octapharma Corporate Summary
7.4.2 Octapharma Business Overview
7.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.4.4 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.4.5 Octapharma Key News
7.5 Momenta Pharmaceuticals
7.5.1 Momenta Pharmaceuticals Corporate Summary
7.5.2 Momenta Pharmaceuticals Business Overview
7.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.5.4 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.5.5 Momenta Pharmaceuticals Key News
7.6 Mitsubishi Tanabe Pharma Corporation
7.6.1 Mitsubishi Tanabe Pharma Corporation Corporate Summary
7.6.2 Mitsubishi Tanabe Pharma Corporation Business Overview
7.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.6.4 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.6.5 Mitsubishi Tanabe Pharma Corporation Key News
7.7 Kedrion
7.7.1 Kedrion Corporate Summary
7.7.2 Kedrion Business Overview
7.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.7.4 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.7.5 Kedrion Key News
7.8 Grifols
7.8.1 Grifols Corporate Summary
7.8.2 Grifols Business Overview
7.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.8.4 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.8.5 Grifols Key News
7.9 CSL Behring (CSL Limited)
7.9.1 CSL Behring (CSL Limited) Corporate Summary
7.9.2 CSL Behring (CSL Limited) Business Overview
7.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.9.4 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.9.5 CSL Behring (CSL Limited) Key News
7.10 Bio Products Laboratory
7.10.1 Bio Products Laboratory Corporate Summary
7.10.2 Bio Products Laboratory Business Overview
7.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.10.4 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.10.5 Bio Products Laboratory Key News
7.11 Baxter
7.11.1 Baxter Corporate Summary
7.11.2 Baxter Business Overview
7.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.11.4 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.11.5 Baxter Key News
7.12 MedDay Pharmaceuticals
7.12.1 MedDay Pharmaceuticals Corporate Summary
7.12.2 MedDay Pharmaceuticals Business Overview
7.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.12.4 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.12.5 MedDay Pharmaceuticals Key News
7.13 GeNeuro Pharmaceuticals
7.13.1 GeNeuro Pharmaceuticals Corporate Summary
7.13.2 GeNeuro Pharmaceuticals Business Overview
7.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings
7.13.4 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)
7.13.5 GeNeuro Pharmaceuticals Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunities & Trends in Global Market
Table 2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers in Global Market
Table 3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints in Global Market
Table 4. Key Players of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Global Market
Table 5. Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Companies, 2017-2022
Table 8. Global Companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Type
Table 9. List of Global Tier 1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2023-2028
Table 30. Teijin Pharma Corporate Summary
Table 31. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 32. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 33. Shire Corporate Summary
Table 34. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 35. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 36. Pfizer Corporate Summary
Table 37. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 38. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 39. Octapharma Corporate Summary
Table 40. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 41. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 42. Momenta Pharmaceuticals Corporate Summary
Table 43. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 44. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 45. Mitsubishi Tanabe Pharma Corporation Corporate Summary
Table 46. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 47. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 48. Kedrion Corporate Summary
Table 49. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 50. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 51. Grifols Corporate Summary
Table 52. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 53. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 54. CSL Behring (CSL Limited) Corporate Summary
Table 55. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 56. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 57. Bio Products Laboratory Corporate Summary
Table 58. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 59. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 60. Baxter Corporate Summary
Table 61. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 62. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 63. MedDay Pharmaceuticals Corporate Summary
Table 64. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 65. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 66. GeNeuro Pharmaceuticals Corporate Summary
Table 67. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 68. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunities & Trends in Global Market
Table 2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers in Global Market
Table 3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints in Global Market
Table 4. Key Players of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Global Market
Table 5. Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Companies, 2017-2022
Table 8. Global Companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Type
Table 9. List of Global Tier 1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2023-2028
Table 30. Teijin Pharma Corporate Summary
Table 31. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 32. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 33. Shire Corporate Summary
Table 34. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 35. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 36. Pfizer Corporate Summary
Table 37. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 38. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 39. Octapharma Corporate Summary
Table 40. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 41. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 42. Momenta Pharmaceuticals Corporate Summary
Table 43. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 44. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 45. Mitsubishi Tanabe Pharma Corporation Corporate Summary
Table 46. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 47. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 48. Kedrion Corporate Summary
Table 49. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 50. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 51. Grifols Corporate Summary
Table 52. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 53. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 54. CSL Behring (CSL Limited) Corporate Summary
Table 55. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 56. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 57. Bio Products Laboratory Corporate Summary
Table 58. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 59. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 60. Baxter Corporate Summary
Table 61. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 62. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 63. MedDay Pharmaceuticals Corporate Summary
Table 64. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 65. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
Table 66. GeNeuro Pharmaceuticals Corporate Summary
Table 67. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings
Table 68. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US$, Mn), (2017-2022)
LIST OF FIGURES
Figure 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Segment by Type in 2021
Figure 2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Segment by Application in 2021
Figure 3. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2021
Figure 8. By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 9. By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 10. By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 11. By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 12. US Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 16. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 17. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 24. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 28. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 30. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 33. Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 37. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Segment by Type in 2021
Figure 2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Segment by Application in 2021
Figure 3. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2021
Figure 8. By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 9. By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 10. By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 11. By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 12. US Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 16. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 17. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 24. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 28. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 30. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028
Figure 33. Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US$, Mn), 2017-2028
Figure 37. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
